Systems biology and functional genomics approaches for the identification of cellular responses to drug toxicity

Expert Opinion on Drug Metabolism and Toxicology

Volumn 4, Issue 11, 2008, Pages 1379-1389

  Harrill, Alison Hege ^a   Rusyn, Ivan ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b University of North Carolina at Chapel Hill   (United States)

Author keywords

High throughput toxicity screening; Susceptibility; Systems biology; Toxicogenetics; Toxicogenomics

Indexed keywords

ABACAVIR; ALCOHOL; ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER; COUMARIN; IRINOTECAN; MERCAPTOPURINE; PARACETAMOL; TESTOSTERONE; THIOACETAMIDE; WARFARIN; XENOBIOTIC AGENT;

CARCINOGENICITY; CELL DAMAGE; CLINICAL TRIAL; DRUG EXPOSURE; DRUG METABOLISM; DRUG SAFETY; DRUG TOXICITY; DRUG TRANSFORMATION; FUNCTIONAL GENOMICS; GENE EXPRESSION PROFILING; GENETIC DATABASE; GENETIC MODEL; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HEALTH HAZARD; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; LIVER INJURY; LIVER TOXICITY; METABOLOMICS; MOLECULAR BIOLOGY; NONHUMAN; PARKINSON DISEASE; PHENOTYPE; PROTEOMICS; QUANTITATIVE TRAIT LOCUS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STRUCTURAL GENOMICS; SYSTEMS BIOLOGY; TOXICITY TESTING; TOXICOGENETICS; TRANSCRIPTOMICS;

ANIMALS; BIOTECHNOLOGY; GENE EXPRESSION PROFILING; HUMANS; PHARMACEUTICAL PREPARATIONS; SYSTEMS BIOLOGY; TOXICOGENETICS;

EID: 56749122303     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.4.11.1379     Document Type: Review

References (95)

1. Gutman S, Hackett J. Search for shortcuts on the critical path to market: US FDA perspectives from the diagnostic side. Pharmacogenomics 2006;7(8):1223-7
2. U.S. Food and Drug Administration. Guidance for Industry: pharmacogenomic data submissions. 2005
3. Frueh FW. Impact of microarray data quality on genomic data submissions to the FDA. Nat Biotechnol 2006;24(9):1105-7
4. Bammler T, Beyer RP, Bhattacharya S, et al. Standardizing global gene expression analysis between laboratories and across platforms. Nat Methods 2005;2(5):351-6
5. Shi L, Reid LH, Jones WD, et al. The MicroArray Quality Control (MAQC) project shows inter- and intraplatform. reproducibility of gene expression measurements. Nat Biotechnol 2006;24(9):1151-61
6. Beyer RP, Fry RC, Lasarev MR, et al. Multicenter study of acetaminophen hepatotoxicity reveals the importance of biological endpoints in genomic analyses. Toxicol Sci 2007;99(1):326-37
7. Ishkanian AS, Malloff CA, Watson SK, et al. A tiling resolution DNA microarray with complete coverage of the human genome. Nat Genet 2004;36(3):299-303
8. Arcellana-Panlilio M, Robbins SM. Cutting-edge technology. I. Global gene expression profiling using DNA microarrays. Am J Physiol Gastrointest Liver Physiol 2002;282(3):G397-402
9. Paules R. Phenotypic anchoring: linking cause and effect. Environ Health Perspect 2003;111(6):A338-9
10. Powell CL, Kosyk O, Ross PK, et al. Phenotypic anchoring of acetaminophen-induced oxidative stress with gene expression profiles in rat liver. Toxicol Sci 2006;93(1):213-22
11. Heinloth AN, Irwin RD, Boorman GA, et al. Gene expression profiling of rat livers reveals indicators of potential adverse effects. Toxicol Sci 2004;80(1):193-202
12. Wang EJ, Snyder RD, Fielden MR, et al. Validation of putative genomic biomarkers of nephrotoxicity in rats. Toxicology 2008;246(2-3):91-100
13. Khor TO, Ibrahim S, Kong AN. Toxicogenomics in drug discovery and drug development: potential applications and future challenges. Pharm Res 2006;23(8):1659-64
14. Ridd K, Zhang SD, Edwards RE, et al. Association of gene expression with sequential proliferation, differentiation and tumor formation in murine skin. Carcinogenesis 2006;27(8):1556-66
15. Christians U, Schmitz V, Schoning W, et al. Toxicodynamic therapeutic drug monitoring of immunosuppressants: promises, reality, and challenges. Ther Drug Monit 2008;30(2):151-8
16. Bushel PR, Heinloth AN, Li J, et al. Blood gene expression signatures predict exposure levels. Proc Natl Acad Sci USA 2007;104(46):18211-6
17. Burczynski ME, McMillian M, Ciervo J, et al. Toxicogenomics-based discrimination of toxic mechanism in HepG2 human hepatoma cells. Toxicol Sci 2000;58(2):399-415
18. Waring JF, Ulrich RG, Flint N, et al. Interlaboratory evaluation of rat hepatic gene expression changes induced by methapyrilene. Environ Health Perspect 2004;112(4):439-48
19. Hamadeh HK, Bushel PR, Jayadev S, et al. Gene expression analysis reveals chemical-specific profiles. Toxicol Sci 2002;67(2):219-31
20. Inadera H, Tachibana S, Takasaki I, et al. Expression profile of liver genes in response to hepatotoxicants identified using a SAGE-based customized DNA microarray system. Toxicol Lett 2008;177(1):20-30
21. Dai X, He YD, Dai H, et al. Development of an approach for ab initio estimation of compound-induced liver injury based on global gene transcriptional profiles. Genome Inform 2006;17(2):77-88
22. Fielden MR, Brennan R, Gollub J. A gene expression biomarker provides early prediction and mechanistic assessment of hepatic tumor induction by nongenotoxic chemicals. Toxicol Sci 2007;99(1):90-100
23. Eun JW, Ryu SY, Noh JH, et al. Discriminating the molecular basis of hepatotoxicity using the large-scale characteristic molecular signatures of toxicants by expression profiling analysis. Toxicology 2008;249(2-3):176-83
24. Bartosiewicz MJ, Jenkins D, Penn S, et al. Unique gene expression patterns in liver and kidney associated with exposure to chemical toxicants. J Pharmacol Exp Ther 2001;297(3):895-905
25. McMillian M, Nie AY, Parker JB, et al. Inverse gene expression patterns for macrophage activating hepatotoxicants and peroxisome proliferators in rat liver. Biochem Pharmacol 2004;67(11):2141-65
26. Harries HM, Fletcher ST, Duggan CM, Baker VA. The use of genomics technology to investigate gene expression changes in cultured human liver cells. Toxicol In Vitro 2001;15(4-5):399-405
27. Uehara T, Kiyosawa N, Shimizu T, et al. Species-specific differences in coumarin-induced hepatotoxicity as an example toxicogenomics-based approach to assessing risk of toxicity to hurnans. Hum Exp Toxicol 2008;27(1):23-35
28. Elferink MG, Olinga P, Draaisma AL, et al. Microarray analysis in rat liver slices correctly predicts in vivo hepatotoxicity. Toxicol Appl Pharmacol 2008;229(3):300-9
29. Lerche-Langrand C, Toutain HJ. Precision-cut liver slices: characteristics and use for in vitro pharmaco-toxicology. Toxicology 2000;153(1-3):221-53
30. Adachi Y, Bradford BU, Gao W, et al. Inactivation of Kupffer cells prevents early alcohol-induced liver injury. Hepatology 1994;20(2):453-60
31. Wheeler MD, Kono H, Yin M, et al. The role of Kupffer cell oxidant production in early ethanol-induced liver disease. Free Radic Biol Med 2001;31(12):1544-9
32. Kumagai K, Kiyosawa N, Ito K, et al. Influence of Kupffer cell inactivation on cycloheximide-induced hepatic injury. Toxicology 2007;241(3):106-18
33. Andres D, Sanchez-Reus I, Bautista M, Cascales M. Depletion of Kupffer cell function by gadolinium chloride attenuates thioacetamide-induced hepatotoxicity. Expression of metallothionein and HSP70. Biochem Pharmacol 2003;66(6):917-26
34. Ito Y, Bethea NW, Abril ER, McCuskey RS. Early hepatic microvascular injury in response to acetaminophen toxicity. Microcirculation 2003;10(5):391-400
35. National Research Council. Toxicity Testing in the 21st Century: A Vision and a Strategy. Washington, DC: National Academies Press. 2007
36. Gene Ontology. Available from: www.geneontology.org
37. Gene Map Annotator and Pathway Profiler. Available from: www.genmapp.org
38. Science Signaling Connections Map. Available from: stke.sciencemag.org/cm
39. BioCarta. Available from: www.biocarta.com/genes/index.asp
40. Reactome. Available from: www.genomeknowledge.org
41. KEGG. Available from: www.genome.jp/kegg/pathway.html
42. Zeeberg BR, Feng W, Wang G, et al. GoMiner: a resource for biological interpretation of genomic and proteomic data. Genome Biol 2003;4(4):R28
43. Barry WT, Nobel AB, Wright FA. Significance analysis of functional categories in gene expression studies: a structured permutation approach. Bioinformatics 2005;21(9):1943-9
44. Khatri P, Bhavsar P, Bawa G, Draghici S. Onto-Tools: an ensemble of web-accessible, ontology-based tools for the functional design and interpretation of high-throughput gene expression experiments. Nucleic Acids Res 2004;32(Web Server issue):W449-56
45. Burns JJ. IV. Pharmacogenetics and drug toxicity. Variation of drug metabolism in animals and the prediction of drug action in man. Ann N Y Acad Sci 1968;151(2):959-67
46. Kalow W. Contribution of hereditary factors to the response to drugs. Fed Proc 1965;24(6):1259-65
47. Vesell ES, Page JG. Genetic control of dicumarol levels in man. J Clin Invest 1968;47(12):2657-63
48. Nebert DW, Zhang G, Vesell ES. From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions. Drug Metab Rev 2008;40(2):187-224
49. Cacabelos R. Pharmacogenetic basis for therapeutic optimization in Alzheimer's disease. Mol Diagn Ther 2007;11(6):385-405
50. Yates CR, Krynetski EY, Loennechen T, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997;126(8):608-14
51. Relling MV, Hancock ML, Rivera GK, et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 1999;91(23):2001-8
52. Rost S, Fregin A, Ivaskevicius V, et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 2004;427(6974):537-41
53. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. J Am Med Assoc 2002;287(13):1690-8
54. Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005;352(22):2285-93
55. Weinshilboum RM, Wang L. Pharmacogenetics and pharmacogenomics: development, science, and translation. Annu Rev Genomics Hum Genet 2006;7:223-45
56. Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science 2001;291(5507):1304-51
57. Weiss ST, McLeod HL, Flockhart DA, et al. Creating and evaluating genetic tests predictive of drug response. Nat Rev Drug Discov 2008;7(7):568-74
58. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008;358(6):568-79
59. Nebert DW, Vesell ES. Advances in pharmacogenomics and individualized drug therapy: exciting challenges that lie ahead. Eur J Pharmacol 2004;500(1-3):267-80
60. Ioannidis JP, Trikalinos TA, Ntzani EE, Contopoulos-Ioannidis DG. Genetic associations in large versus small studies: an empirical assessment. Lancet 2003;361(9357):567-71
61. Ntzani EE, Rizos EC, Ioannidis JP. Genetic effects versus bias for candidate polymorphisms in myocardial infarction: case study and overview of large-scale evidence. Am J Epidemiol 2007;165(9):973-84
62. Lesnick TG, Papapetropoulos S, Mash DC, et al. A genomic pathway approach to a complex disease: axon guidance and Parkinson disease. PLoS Genet 2007;3(6):e98
63. Donfack J, Buchinsky FJ, Post JC, Ehrlich GD. Human susceptibility to viral infection: the search for HIV-protective alleles among Africans by means of genome-wide studies. AIDS Res Hum Retroviruses 2006;22(10):925-30
64. McClurg P, Pletcher MT, Wiltshire T, Su AI. Comparative analysis of haplotype association mapping algorithms. BMC Bioinformatics 2006;7:61
65. Frazer KA, Eskin E, Kang HM, et al. A sequence-based variation map of 8.27 million SNPs in inbred mouse strains. Nature 2007;448(7157):1050-3
66. Pletcher MT, McClurg P, Batalov S, et al. Use of a dense single nucleotide polymorphism map for in silico mapping in the mouse. PLoS Biol 2004;2(12):e393
67. Guo Y, Weller P, Farrell E, et al. In silico pharmacogenetics of warfarin metabolism. Nat Biotechnol 2006;24(5):531-6
68. Guo Y, Lu P, Farrell E, et al. In silico and in vitro pharmacogenetic analysis in mice. Proc Natl Acad Sci USA 2007;104(45):17735-40
69. Churchill GA, Airey DC, Allayee H, et al. The Collaborative Cross, a community resource for the genetic analysis of complex traits. Nat Genet 2004;36(11):1133-7
70. Roberts A, Pardo-Manuel de Villena F, Wang W, et al. The polymorphism architecture of mouse genetic resources elucidated using genome-wide resequencing data: implications for QTL discovery and systems genetics. Mamm Genome 2007;18(6-7):473-81
71. Wang K, Li M, Bucan M. Pathway-Based Approaches for Analysis of Genomewide Association Studies. Am J Hum Genet 2007;81(6)
72. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005;102(43):15545-50
73. Collison M, Glazier AM, Graham D, et al. Cd36 and molecular mechanisms of insulin resistance in the stroke-prone spontaneously hypertensive rat. Diabetes 2000;49(12):2222-6
74. Karp CL, Grupe A, Schadt E, et al. Identification of complement factor 5 as a susceptibility locus for experimental allergic asthma. Nat Immunol 2000;1(3):221-6
75. Hitzemann R, Reed C, Malmanger B, et al. On the integration of alcohol-related quantitative trait loci and gene expression analyses. Alcohol Clin Exp Res 2004;28(10):1437-48
76. Cook DN, Wang S, Wang Y, et al. Genetic regulation of endotoxin-induced airway disease. Genomics 2004;83(6):961-9
77. Chesler EJ, Lu L, Shou S, et al. Complex trait analysis of gene expression uncovers polygenic and pleiotropic networks that modulate nervous system function. Nat Genet 2005;37(3):233-42
78. Nebert DW, Jorge-Nebert L, Vesell ES. Pharmacogenomics and "individualized drug therapy": high expectations and disappointing achievements. Am J Pharmacogenomics 2003;3(6):361-70
79. Phipps AN, Stewart J, Wright B, Wilson ID. Effect of diet on the urinary excretion of hippuric acid and other dietary-derived aromatics in rat. A complex interaction between diet, gut microflora and substrate specificity. Xenobiotica 1998;28(5):527-37
80. Schrattenholz A, Soskic V. What does systems biology mean for drug development? Curr Med Chem 2008;15(15):1520-8
81. Thomas CE, Ganji G. Integration of genomic and metabonomic data in systems biology-are we 'there' yet? Curr Opin Drug Discov Devel 2006;9(1):92-100
82. Ippolito JE, Xu J, Jain S, et al. An integrated functional genomics and metabolomics approach for defining poor prognosis in human neuroendocrine cancers. Proc Natl Acad Sci USA 2005;102(28):9901-6
83. Li Z, Srivastava S, Mittal S, et al. A Three Stage Integrative Pathway Search (TIPS) framework to identify toxicity relevant genes and pathways. BMC Bioinformatics 2007;8:202
84. Verhoeckx KC, Bijlsma S, de Groene EM, et al. A combination of proteomics, principal component analysis and transcriptomics is a powerful tool for the identification of biomarkers for macrophage maturation in the U937 cell line. Proteomics 2004;4(4):1014-28
85. Hirai MY, Klein M, Fujikawa Y, et al. Elucidation of gene-to-gene and metabolite-to-gene networks in arabidopsis by integration of metabolomics and transcriptomics. J Biol Chem 2005;280(27):25590-5
86. Clayton TA, Lindon JC, Cloarec O, et al. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 2006;440(7087):1073-7
87. Comparative Toxicogenomics Database. Available from: ctd.mdibl.org
88. Distributed Structure-Searchable Toxicity Database. Available from: www.epa.gov/ncct/dsstox/index.html
89. Critical Path Institute. Available from: www.c-path.org
90. Genelogic Database. Available from: www.genelogic.com
91. Iconix Pharmaceuticals Database. Available from: www.iconixbiosciences.com
92. Ceetox Database. Available from: www.ceetox.com
93. Fostel JM. Future of toxicogenomics and safety signatures: balancing public access to data with proprietary drug discovery. Pharmacogenomics 2007;8(5):425-30
94. Yang L, Allen BC, Thomas RS. BMDExpress: a software tool for the benchmark dose analyses of genomic data. BMC Genomics 2007;8:387
95. Chesler EJ, Miller DR, Branstetter LR, et al. The Collaborative Cross at Oak Ridge National Laboratory: developing a powerful resource for systems genetics. Mamm Genome In Press